|
1
|
Liu W, Xie Z, Shen K, Jiang L, Liu C, Ge Y, Yu J, Jia W, Ma J, Chen H. Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinoma. Med Oncol 2023; 40:251. [PMID: 37498394 DOI: 10.1007/s12032-023-02082-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Accepted: 06/05/2023] [Indexed: 07/28/2023]
Abstract
To evaluate the effectiveness and safety of transarterial chemoembolization (TACE) combined with immune and targeted therapy in unresectable hepatocellular carcinoma (HCC). Prospective analysis of 23 patients with intermediate or advanced primary HCC treated at the Department of Hepatic Surgery, The First Affiliated Hospital of the University of Science and Technology of China from July 2019, including 11 cases treated with TACE alone and 12 cases treated with TACE combined with targeted therapy. The basal indexes of patients in the two groups were compared, and the response during treatment was observed; regular follow-up was performed to assess the efficacy of tumor treatment. Compared with TACE treatment alone, the objective response rate (ORR) was significantly higher in the TACE combined with targeted treatment group (50.0% vs 36.4%), with a higher success rate of surgical conversion (33.3% vs 18.2%) and a significantly longer progression-free survival (PFS) (20.5 ± 2.9 months vs 11.6 ± 2.9 months). Multifactorial regression analysis identified tumor vascular invasion as an independent prognostic factor affecting HCC. No patient experienced catheter retention-related complications during treatment, and there were no intolerable adverse effects. TACE combined with targeted treatment for intermediate to advanced unresectable HCC was effective, with good tumor responsiveness, high surgical conversion rate, and safe and controllable adverse reactions during treatment.
Collapse
Affiliation(s)
- Wenbin Liu
- Division of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China
- First Clinical Medical College, Anhui Medical University, Hefei, 230001, Anhui, China
| | - Zhiguo Xie
- Division of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China
- First Clinical Medical College, Anhui Medical University, Hefei, 230001, Anhui, China
| | - Kefeng Shen
- Division of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China
- First Clinical Medical College, Anhui Medical University, Hefei, 230001, Anhui, China
| | - Lizhu Jiang
- Division of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China
- First Clinical Medical College, Anhui Medical University, Hefei, 230001, Anhui, China
| | - Chongyan Liu
- Division of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China
- First Clinical Medical College, Anhui Medical University, Hefei, 230001, Anhui, China
| | - Yongsheng Ge
- Division of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China
- First Clinical Medical College, Anhui Medical University, Hefei, 230001, Anhui, China
| | - Jihai Yu
- Division of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China
- First Clinical Medical College, Anhui Medical University, Hefei, 230001, Anhui, China
| | - Weidong Jia
- Division of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China
- First Clinical Medical College, Anhui Medical University, Hefei, 230001, Anhui, China
| | - Jinliang Ma
- Division of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China
- First Clinical Medical College, Anhui Medical University, Hefei, 230001, Anhui, China
| | - Hao Chen
- Division of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China.
- First Clinical Medical College, Anhui Medical University, Hefei, 230001, Anhui, China.
| |
Collapse
|
|
3
|
Chen H, Wang Y, Xie Z, Zhang L, Ge Y, Yu J, Zhang C, Jia W, Ma J, Liu W. Application Effect of ICG Fluorescence Real-Time Imaging Technology in Laparoscopic Hepatectomy. Front Oncol 2022; 12:819960. [PMID: 35463377 PMCID: PMC9020263 DOI: 10.3389/fonc.2022.819960] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Accepted: 03/07/2022] [Indexed: 01/24/2023] Open
Abstract
This study aimed to evaluate the efficiency and safety of indocyanine green (ICG) fluorescence real-time imaging-guided technology in laparoscopic hepatectomy. A retrospective analysis of patients with primary liver cancer in the First Affiliated Hospital of USTC from January 2018 to October 2021, including 48 cases of fluorescence-guided laparoscopic hepatectomy (FGLH) and 60 cases of traditional laparoscopic hepatectomy (LH), was conducted. R0 resection rate, operation time, intraoperative blood loss, complications, hospital stay, and other intraoperative and postoperative indicators of the two groups were analyzed to determine the clinical feasibility and safety of ICG fluorescence real-time imaging-guided technology in laparoscopic hepatectomy. Related databases were searched for retrospective cohort studies and randomized controlled trials comparing FGLH with LH, studies were screened according to preset inclusion and exclusion criteria, literature quality was evaluated, and data were extracted. RevMan 5.3 software was used to conduct a meta-analysis on the extracted data. The results of our clinical data and meta-analysis showed that compared with LH, FGLH increased the R0 resection rate, shortened the operation time and postoperative hospital stay, and reduced blood loss and the occurrence of postoperative complications. Compared with LH, FGLH has a better application effect in laparoscopic hepatectomy, and it is worthy of promotion as it is safe and feasible.
Collapse
Affiliation(s)
- Hao Chen
- Department of Hepatic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
| | - Yumin Wang
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, China
| | - Zhiguo Xie
- Department of Hepatic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.,Department of General Surgery, Wannan Medical College, Wuhu, China
| | - Luyuan Zhang
- Department of Neurosurgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - Yongsheng Ge
- Department of Hepatic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
| | - Jihai Yu
- Department of Hepatic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
| | - Chuanhai Zhang
- Department of Hepatic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
| | - Weidong Jia
- Department of Hepatic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
| | - Jinliang Ma
- Department of Hepatic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
| | - Wenbin Liu
- Department of Hepatic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
| |
Collapse
|